Lb Pharmaceuticals (LBRX) Cash & Equivalents (2024 - 2026)

Lb Pharmaceuticals' Cash & Equivalents history runs 3 years deep, the most recent figure standing at $320.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents changed N/A year-over-year to $320.7 million; the TTM figure through Mar 2026 stood at $320.7 million (changed N/A YoY), while the FY2025 annual figure was $250.2 million, up 988.75% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $320.7 million, up from $250.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $320.7 million in Q1 2026, with the low at $23.0 million in Q4 2024.
• The 3-year median for Cash & Equivalents is $260.0 million (2025), against an average of $215.9 million.
• Peak annual rise in Cash & Equivalents reached 988.75% in 2025, while the deepest fall reached 988.75% in 2025.
• Lb Pharmaceuticals' Cash & Equivalents stood at $23.0 million in 2024, then soared by 988.75% to $250.2 million in 2025, then increased by 28.18% to $320.7 million in 2026.
• Business Quant data shows LBRX's Cash & Equivalents at $320.7 million in Q1 2026, $250.2 million in Q4 2025, and $269.7 million in Q3 2025.